Published in Brain Res on May 03, 1991
Therapeutic potential of protein kinase C inhibitors. Agents Actions (1993) 1.02
Oxygen deprivation inhibits Na+ current in rat hippocampal neurones via protein kinase C. J Physiol (1997) 0.88
The vulnerability of nitrergic neurons to transient spinal cord ischemia: a quantitative immunohistochemical and histochemical study. J Mol Histol (2012) 0.77
The Growth of Certain Bacteria in Media of Different Hydrogen Ion Concentrations. J Bacteriol (1919) 47.74
COLON BACTERIA AND STREPTOCOCCI AND THEIR SIGNIFICANCE IN MILK. Am J Public Health (N Y) (1916) 13.94
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
The Characteristics of Bacteria of the Colon Type Occurring in Human Feces. J Bacteriol (1918) 8.50
SOME CONDITIONS AFFECTING THE PRODUCTION OF GELATINASE BY PROTEUS BACTERIA. J Bacteriol (1928) 6.01
A NOTE ON PENFOLD'S MODIFICATION OF BACILLUS COLI COMMUNIS. Science (1913) 4.45
Urease Activity as Influenced by Oxidation and Reduction. Proc Natl Acad Sci U S A (1933) 4.28
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology (2007) 3.56
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol (1992) 3.49
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA (2000) 3.17
Spontaneous early improvement following ischemic stroke. Stroke (1995) 2.13
Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science (1985) 2.10
Prospective reliability of the STRokE DOC wireless/site independent telemedicine system. Neurology (2005) 2.08
Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system. Cell (1987) 1.90
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 1.71
A Potentiometric Study of Epinephrine. Proc Natl Acad Sci U S A (1931) 1.70
How to analyze binding, enzyme and uptake data: the simplest case, a single phase. Life Sci (1982) 1.49
Rotational vertebral artery occlusion: a mechanism of vertebrobasilar insufficiency. Neurosurgery (1997) 1.47
Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol (1995) 1.30
Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev (1993) 1.25
Distribution of biogenic amines and related enzymes in the rat pituitary gland. J Neurochem (1975) 1.24
Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol (1988) 1.23
Assembly of proteins to postsynaptic densities after transient cerebral ischemia. J Neurosci (1998) 1.22
Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes. Neuroscience (2007) 1.18
Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience (2007) 1.18
Spinal cord infarction: a highly reproducible stroke model. Stroke (1980) 1.16
Normal interpediculate distances (minimum and maximum) in children and adults. Am J Roentgenol Radium Ther Nucl Med (1966) 1.15
Modification of postsynaptic densities after transient cerebral ischemia: a quantitative and three-dimensional ultrastructural study. J Neurosci (1999) 1.13
Neuropathology of experimental spinal cord ischemia in the rabbit. J Neuropathol Exp Neurol (1982) 1.13
The STRokE DOC trial technique: 'video clip, drip, and/or ship'. Int J Stroke (2007) 1.12
Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke (2000) 1.12
Sagittal diameter of the lumbar spinal canal in children and adults. Radiology (1965) 1.11
Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol (1988) 1.09
Persistent inflammatory response in stroke survivors. Neurology (1998) 1.08
Cell transplant therapy for stroke: hope or hype. Neurology (2000) 1.07
Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res (1975) 1.07
Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke (1990) 1.05
The normal closure of the ventricular septum. Am Heart J (1967) 1.04
Spectrum of neurological deficits in experimental CNS ischemia. A quantitative study. Arch Neurol (1982) 1.03
Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg (1991) 1.02
Community pharmacists' knowledge and dispensing recommendations for treatment of acute diarrhoea in Trinidad, West Indies. Int J Clin Pract (2004) 1.02
Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol (1993) 1.01
Temporal modulation of cytokine expression following focal cerebral ischemia in mice. Brain Res (1999) 1.01
Effects of glycine on hemodynamic responses and visual evoked potentials in the dog. Anesth Analg (1985) 0.99
Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA(A) receptors. Stroke (2000) 0.99
Benign angioedema after thrombolysis for acute stroke. J Stroke Cerebrovasc Dis (2007) 0.97
Persistent phosphorylation of cyclic AMP responsive element-binding protein and activating transcription factor-2 transcription factors following transient cerebral ischemia in rat brain. Neuroscience (1999) 0.96
Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke (1999) 0.96
Statistics for disinterested scientists. Life Sci (1976) 0.94
Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology (1995) 0.94
Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR Am J Neuroradiol (1994) 0.94
Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke (1991) 0.93
Reduction of neurological damage by a peptide segment of the amyloid beta/A4 protein precursor in a rabbit spinal cord ischemia model. Exp Neurol (1994) 0.93
Detection of arterial emboli using Doppler ultrasound in rabbits. Stroke (1991) 0.93
Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res (1987) 0.91
Fiber intakes, stool frequency, and stool weights of subjects consuming self-selected diets. Am J Clin Nutr (1984) 0.90
Changes in expression of the DNA repair protein complex DNA-dependent protein kinase after ischemia and reperfusion. J Neurosci (1999) 0.90
Acute hypertension promotes hemorrhagic transformation in a rabbit embolic stroke model: effect of labetalol. Exp Neurol (1998) 0.90
Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. Am J Med (1992) 0.90
Biochemical and histochemical studies of biogenic amines in spinal cord trauma. Neurology (1976) 0.90
Ultrasound patterns of disorders affecting the gastrointestinal tract. Radiology (1980) 0.89
The role of angioplasty in the treatment of cerebrovascular disease. Neurosurgery (1998) 0.89
The spectrum of small bowel melanoma. Gastrointest Radiol (1978) 0.89
Drug eluting stents for symptomatic intracranial and vertebral artery stenosis. Interv Neuroradiol (2011) 0.88
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology (1989) 0.88
Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol (1996) 0.87
The initial acute phase response predicts long-term stroke recovery. J Stroke Cerebrovasc Dis (2007) 0.87
Spondylolisthesis of the axis vertebra. AJR Am J Roentgenol (1977) 0.84
A model for quantitative evaluation of embolic stroke therapy. Brain Res (1987) 0.84
Naloxone in experimental spinal cord ischemia: dose-response studies. Eur J Pharmacol (1984) 0.83
Quantitative effects of cerebral infarction on spatial learning in rats. Exp Neurol (1992) 0.83
Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke. J Pharmacol Exp Ther (1993) 0.83
Microalbuminuria in ischemic stroke. Arch Neurol (1999) 0.83
THE PRODUCTION OF VOLATILE FATTY ACIDS BY BACTERIA OF THE DYSENTERY GROUP. J Gen Physiol (1921) 0.83
Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. Arch Neurol (1987) 0.82
Intracranial intraarterial thrombolysis facilitated by microcatheter navigation through an occluded cervical internal carotid artery. J Neurosurg (1996) 0.82
Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation (1994) 0.82
Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke (1994) 0.82
Continuous intrathecal fluid infusions elevate nerve growth factor levels and prevent functional deficits after spinal cord ischemia. Brain Res (2000) 0.82
A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke (1994) 0.82
Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques. Atherosclerosis (1993) 0.82
Donor eye contamination. Am J Ophthalmol (1982) 0.82
Atherosclerotic plaque growth: presence of stimulatory fibrin degradation products. Blood Coagul Fibrinolysis (1990) 0.81
Inactivation and subcellular redistribution of Ca2+/calmodulin-dependent protein kinase II following spinal cord ischemia. J Neurochem (1993) 0.81
Cervical spine trauma: the common combined conditions. Radiology (1979) 0.81
Effect of ischemic cerebral volume changes on behavior. Behav Brain Res (1997) 0.80
Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis. J Stroke Cerebrovasc Dis (2007) 0.80
An animal model for low dose ethanol-induced locomotor stimulation: behavioral characteristics. Alcohol Clin Exp Res (1985) 0.80
Spontaneous echo contrast and hemorheologic abnormalities in cerebrovascular disease. Stroke (1994) 0.80
An evoked potential study of limbic projections to nuclei of the cat septum. Electroencephalogr Clin Neurophysiol (1968) 0.80
Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration. Stroke (1992) 0.79
Activation of nuclear factor-kappaB in the rabbit spinal cord following ischemia and reperfusion. Brain Res Mol Brain Res (1998) 0.79
Leonor Michaelis: 1875-1949. Science (1950) 0.79
Comparison of naloxone and a delta-selective antagonist in experimental spinal stroke. Life Sci (1983) 0.79
Reduction of intracerebral hemorrhaging in a rabbit embolic stroke model. Neurology (1999) 0.79